Online citations, reference lists, and bibliographies.

Association Between Use Of Non–Vitamin K Oral Anticoagulants With And Without Concurrent Medications And Risk Of Major Bleeding In Nonvalvular Atrial Fibrillation

Shang‐Hung Chang, I-Jun Chou, Yung‐Hsin Yeh, Meng-Jiun Chiou, Ming-Shien Wen, Chi‐Tai Kuo, Lai‐Chu See, Chang‐Fu Kuo
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Importance Non–vitamin K oral anticoagulants (NOACs) are commonly prescribed with other medications that share metabolic pathways that may increase major bleeding risk. Objective To assess the association between use of NOACs with and without concurrent medications and risk of major bleeding in patients with nonvalvular atrial fibrillation. Design, Setting, and Participants Retrospective cohort study using data from the Taiwan National Health Insurance database and including 91 330 patients with nonvalvular atrial fibrillation who received at least 1 NOAC prescription of dabigatran, rivaroxaban, or apixaban from January 1, 2012, through December 31, 2016, with final follow-up on December 31, 2016. Exposures NOAC with or without concurrent use of atorvastatin; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconazole, itraconazole, voriconazole, or posaconazole; cyclosporine; erythromycin or clarithromycin; dronedarone; rifampin; or phenytoin. Main Outcomes and Measures Major bleeding, defined as hospitalization or emergency department visit with a primary diagnosis of intracranial hemorrhage or gastrointestinal, urogenital, or other bleeding. Adjusted incidence rate differences between person-quarters (exposure time for each person during each quarter of the calendar year) of NOAC with or without concurrent medications were estimated using Poisson regression and inverse probability of treatment weighting using the propensity score. Results Among 91 330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [SD, 10.8]; men, 55.8%; NOAC exposure: dabigatran, 45 347 patients; rivaroxaban, 54 006 patients; and apixaban, 12 886 patients), 4770 major bleeding events occurred during 447 037 person-quarters with NOAC prescriptions. The most common medications co-prescribed with NOACs over all person-quarters were atorvastatin (27.6%), diltiazem (22.7%), digoxin (22.5%), and amiodarone (21.1%). Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin with NOACs had a significant increase in adjusted incidence rates per 1000 person-years of major bleeding than NOACs alone: 38.09 for NOAC use alone vs 52.04 for amiodarone (difference, 13.94 [99% CI, 9.76-18.13]); 102.77 for NOAC use alone vs 241.92 for fluconazole (difference, 138.46 [99% CI, 80.96-195.97]); 65.66 for NOAC use alone vs 103.14 for rifampin (difference, 36.90 [99% CI, 1.59-72.22); and 56.07 for NOAC use alone vs 108.52 for phenytoin (difference, 52.31 [99% CI, 32.18-72.44]; P < .01 for all comparisons). Compared with NOAC use alone, the adjusted incidence rate for major bleeding was significantly lower for concurrent use of atorvastatin, digoxin, and erythromycin or clarithromycin and was not significantly different for concurrent use of verapamil; diltiazem; cyclosporine; ketoconazole, itraconazole, voriconazole, or posaconazole; and dronedarone. Conclusions and Relevance Among patients taking NOACs for nonvalvular atrial fibrillation, concurrent use of amiodarone, fluconazole, rifampin, and phenytoin compared with the use of NOACs alone, was associated with increased risk of major bleeding. Physicians prescribing NOAC medications should consider the potential risks associated with concomitant use of other drugs.
This paper references
The central role of the propensity score in observational studies for causal effects
P. Rosenbaum (1983)
A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.
X. Delavenne (2013)
Coadministration of Dabigatran Etexilate and Atorvastatin
J. Stangier (2009)
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin
J Stangier (2012)
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Yi-Hsin Chan (2016)
Confounding and indication for treatment in evaluation of drug treatment for hypertension
D. Grobbee (1997)
Bleeding associated with coadministration of rivaroxaban and clarithromycin
M. Fralick (2016)
Novel anticoagulants—an update on the latest developments and management for Research Original Investigation Bleeding Risk in Nonvalvular AF on NOACs With vs Without Other Medications
B Green (2017)
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.
H. Heidbuchel (2013)
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary
H. Heidbuchel (2017)
Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation.
Sally Tamayo (2016)
Statin Therapy and the Risk of Intracerebral Hemorrhage: A Meta-Analysis of 31 Randomized Controlled Trials
J. McKinney (2012)
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
M. Gerhard-Herman (2017)
In Vitro Predictability of Drug-Drug Interaction Likelihood of P-Glycoprotein-Mediated Efflux of Dabigatran Etexilate Based on [I]2/IC50 Threshold
W. Kishimoto (2014)
Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A.
A. Wannhoff (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
C. Ruff (2014)
Effect of 20 mg/day Atorvastatin: Recurrent Stroke Survey in Chinese Ischemic Stroke Patients with Prior Intracranial Hemorrhage
Wei-hua Jia (2013)
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study.
J. Lunceford (2004)
Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
Yi-Hsin Chan (2016)
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial
K-H Liesenfeld (2011)
Thromboembolic, bleeding, andmortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation
Chan Y-H (2016)
Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation
Yi-Hsin Chan (2016)
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
W. Mueck (2013)
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
R. Pisters (2010)
Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents
C. Ruff (2016)
Anticoagulation in Atrial Fibrillation: Is the Paradigm Really Shifting?
P. Deedwania (2017)
Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study
S. Chugh (2014)
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
J. Olesen (2015)
Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis
Bao-Zhu Li (2015)
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation
J. Piccini (2016)
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
B. Wiggins (2016)
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
G. Flaker (2014)
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
J. Jaspers Focks (2016)
A newmethod of classifying prognostic comorbidity in longitudinal studies: development and validation
CharlsonME (1987)
Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated?: Yes Even 1 Stroke Risk Factor Confers a Real Risk of Stroke
G. Lip (2016)
Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
S. Atar (2006)
ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation
CB Granger (2011)
treated with cyclosporine A
KishimotoW (2014)
Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation
Yishen Wang (2016)
Dabigatran versus warfarin in patients with atrial fibrillation.
S. Connolly (2009)
RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation
SJ Connolly (2009)
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
J. Stangier (2009)
Validation of a combined comorbidity index.
M. Charlson (1994)
Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis
J. Romley (2015)
Apixaban versus warfarin in patients with atrial fibrillation.
C. Granger (2011)
Novel anticoagulants—an update on the latest developments and management for Research Original Investigation Bleeding Risk in Nonvalvular AF on NOACs With vs Without Other Medications
B Green (2017)
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
M. Charlson (1987)
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin
J. Stangier (2012)
High‐dose statin therapy and risk of intracerebral hemorrhage: a meta‐analysis
A. Pandit (2016)
Cardiovascular , bleeding , andmortality risks of dabigatran in Asians with nonvalvular atrial fibrillation
YH Chan (2015)
Novel anticoagulants—an update on the latest developments andmanagement for Research Original Investigation Bleeding Risk in Nonvalvular AF on NOACsWith vsWithout Other Medications
B Green (2017)
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of theARISTOTLE trial.BMJ. 2016;353:i2868
J Jaspers Focks (2016)
Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
D. Parasrampuria (2016)

This paper is referenced by
Increased Risk of Bleeding in Elderly Patients Treated With Oral Anticoagulants and Angiotensin-Converting Enzyme Inhibitors.
Alice Laudisio (2019)
Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding
Mintaek Lee (2020)
Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions
Arne Gessner (2019)
Distinguishing between Individual Direct Oral Anticoagulants on the Basis of their Specific Characteristics
Mami Sakurai (2018)
Drug-drug interactions affecting drug levels of direct oral anticoagulants in the real world: A systematic review
A. Li (2020)
Breaking the rules for studies using real-world observational data: The case of direct-acting anticoagulants and antiepileptic drugs.
Joshua D. K. Brown (2019)
Oral Anticoagulation in Patients With Liver Disease.
A. Qamar (2018)
Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Elodie Jacqueroux (2020)
Response to the "Breaking the rules for studies using real-world observational data: The case of direct acting anticoagulants and antiepileptic drugs by Dr. Brown et al."
C. Wang (2019)
Drug–Drug Interactions with Direct Oral Anticoagulants
Kathrin I. Foerster (2020)
A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge
James A. Josyln (2018)
Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case–control studies
K. Jobski (2019)
Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect
Zhi-chun Gu (2018)
Association of pregnancy outcomes in women with type 2 diabetes treated with metformin versus insulin when becoming pregnant
Shu-Fu Lin (2020)
Pain in the hip: Spontaneous retroperitoneal hemorrhage in an elderly patient on apixaban.
Adil Khan (2019)
[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
A. Enríquez (2019)
Anticoagulación oral en pacientes con hepatopatía
A. Qamar (2018)
Warfarin: The End or the End of One Size Fits All Therapy?
M. Pirmohamed (2018)
Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran
Payal P Kakadiya (2017)
Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016
G. Maura (2019)
Drug Interactions With Non-Vitamin K Oral Anticoagulants.
Nan Wang (2018)
Shorter hospital stay and fewer hospitalisations in patients with visible haematuria on direct oral anticoagulants compared to on vitamin K antagonists.
M. Müller (2019)
Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
Marta Bellesini (2020)
In vitro assessment of P‐gp and BCRP transporter‐mediated drug–drug interactions of riociguat with direct oral anticoagulants
E. Jacqueroux (2019)
Lékové interakce warfarinu a nových, přímých orálních antikoagulancií
Michal Prokeš (2018)
The interactions between anticonvulsants and non-vitamin K antagonist oral anticoagulant agents: a systematic review
Mohamed Taha (2020)
Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation
R. Nissan (2018)
Héparines de bas poids moléculaires dans la maladie thromboembolique veineuse liée au cancer : quelle place en 2019 ?
P. Debourdeau (2020)
Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)
G. Balbi (2020)
Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants.
Kevin Michael Andrew Hill (2020)
Statins and the risk of bleeding in patients taking dabigatran
B. Ho (2019)
A national audit on the utilisation and documentation of dabigatran checklist for patients initiated on dabigatran.
G. Doris (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar